Data compiled by Redley Lamar · ChainSifter Intelligence
9Suppliers
7Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Iovance Biotherapeutics, Inc. (IOVA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
20Total relationships
3Distinct source URLs
13High confidence
0.817Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Iovance Biotherapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
WUXI-ADVANCED-THERAPIES-INC
WUXI-ADVANCED-THERAPIES-INC
92%
Since November 2016, we entered into various manufacturing services agreements with WuXi Advanced Therapies, Inc., and its parent company WuXi Apptec, Co. Ltd, or collectively, WuXi, pursuant to whic…
WUXI-APPTEC-CO-LTD
WUXI-APPTEC-CO-LTD
92%
Since November 2016, we entered into various manufacturing services agreements with WuXi Advanced Therapies, Inc., and its parent company WuXi Apptec, Co. Ltd, or collectively, WuXi, pursuant to whic…
NOVARTIS-PHARMA-AG
NOVARTIS-PHARMA-AG
90%
The Company paid an upfront payment to Novartis and may pay future milestones related to initiation of patient dosing in various phases of clinical development for IOV-3001 and approval of the produc…
The Company will license gene-editing technology from Cellectis S.A. to develop TIL cell therapies that have been genetically edited, including a PD-1 inactivated product that the Company refers to a…
Reciprocal relationship from CLLS graph: Reciprocal relationship from IOVA graph: The Company will license gene-editing technology from Cellectis S.A. to develop TIL cell therapies that have been gen…
NIH
NIH
80%
The Company entered into a patent license agreement with the NIH, an agency of the U.S. Public Health Service within the Department of Health and Human Services, in 2011.
Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or c…
Reciprocal relationship from GNLX graph: g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial.…
Reciprocal relationship from NVSEF graph: Reciprocal relationship from IOVA graph: d Therapies, Inc., or WuXi, WuXi manufactures, packages, ships and handles quality assurance and quality control of …
Iovance Biotherapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
CLINIGEN-SP-LIMITED
CLINIGEN-SP-LIMITED
85%
NOTE 4. PROLEUKIN ® ACQUISITION On January 23, 2023, the Company and its newly formed, wholly owned subsidiary, Iovance Biotherapeutics UK Ltd (the “Purchaser”) entered into an Option Agreement (the …
IOVANCE-BIOTHERAPEUTICS-UK-LTD
IOVANCE-BIOTHERAPEUTICS-UK-LTD
85%
NOTE 4. PROLEUKIN ® ACQUISITION On January 23, 2023, the Company and its newly formed wholly owned subsidiary, Iovance Biotherapeutics UK Ltd (the “Purchaser”) entered into an Option Agreement (the “…
MINARIS-ADVANCED-THERAPIES-INC
MINARIS-ADVANCED-THERAPIES-INC
85%
nter difficulties in production, particularly in scaling up initial production. These problems include difficulties with production costs and yields, quality control, including stability of the produ…
Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or c…
Reciprocal relationship from GNLX graph: ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements w…
Reciprocal relationship from TCRX graph: Reciprocal relationship from IOVA graph: Reciprocal relationship from TCRX graph: ding transposase enzyme, which is derived from sfR fall armyworm, to deliver…
CLINIGEN-HOLDINGS-LIMITED-CLINIGEN-HEALTHCARE-LI
CLINIGEN-HOLDINGS-LIMITED-CLINIGEN-HEALTHCARE-LI
62%
n and manufacturing process, as well as other commercial, clinical, manufacturing, and research settings, which provides additional revenue. In May 2023, we acquired the worldwide rights to Proleukin…
Iovance Biotherapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
IOVA-DEBT-10332
Warrants outstanding: 15754000
90%
xbrl warrant detail from xbrl 2018-12-31.
IOVA-DEBT
Debt stack $47.8M
90%
Market cache reports total debt of $47.8M.
IOVA-DEBT-10333
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2018-12-31.
Iovance Biotherapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Iovance Biotherapeutics, Inc..
Iovance Biotherapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
IOVA-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 289 tracked holders.
Iovance Biotherapeutics, Inc. Extended Supply Chain Network
